-
4 days ago | 
cancertherapyadvisor.com | Erin Clancy
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in lung cancer as well as treatments that fell short of expectations.1-6 Read on for more details on these studies. Results from the phase 3 DeLLphi-304 trial support tarlatamab as a “preferable” second-line therapy for patients with small cell lung cancer (SCLC), according to Charles M.
-
4 days ago | 
shorturl.at | Erin Clancy
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in lung cancer as well as treatments that fell short of expectations.1-6 Read on for more details on these studies. Results from the phase 3 DeLLphi-304 trial support tarlatamab as a “preferable” second-line therapy for patients with small cell lung cancer (SCLC), according to Charles M.
-
5 days ago | 
cancertherapyadvisor.com | Erin Clancy
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances that may inform the treatment of breast cancer.1-10 Read on for more details on these studies.
-
5 days ago | 
shorturl.at | Erin Clancy
Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances that may inform the treatment of breast cancer.1-10 Read on for more details on these studies.
-
1 week ago | 
gastroenterologyadvisor.com | Erin Clancy
Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research as the Trump administration continues to reduce federal research funding.1-3 The administration has now terminated more than 1000 grants issued by the National Institutes of Health (NIH), some in defiance of court orders.4-7 The NIH has also frozen grants to universities and withheld funding from grant recipients who participate in diversity, equity, and inclusion/accessibility...
-
1 week ago | 
oncologynurseadvisor.com | Erin Clancy
Adding niraparib to abiraterone acetate plus prednisone (AAP) and androgen deprivation therapy (ADT) can improve radiographic progression-free survival (rPFS) in patients who have metastatic, castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) mutations, according to phase 3 data presented at the ASCO Annual Meeting 2025.
-
1 week ago | 
clinicaladvisor.com | Erin Clancy
Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...
-
2 weeks ago | 
dermatologyadvisor.com | Erin Clancy
Adjuvant cemiplimab can improve disease-free survival (DFS) in patients with cutaneous squamous cell carcinoma (CSCC) who have completed adjuvant radiotherapy and have a high risk of recurrence, according to research presented at the ASCO Annual Meeting 2025.1 “[C]emiplimab is the only systemic therapy to demonstrate a statistically significant and clinically meaningful reduction in disease recurrence as adjuvant therapy for patients at high risk of CSCC recurrence,” said study presenter...
-
2 weeks ago | 
dermatologyadvisor.com | Erin Clancy
A symptom assessment intervention can reduce acute care use and costs for older adults with cancer, according to a study presented at the ASCO Annual Meeting 2025. The study included 416 patients who had newly diagnosed or relapsed cancer, were 75 years of age and older, and were insured by a Medicare Advantage payer partner. The patients’ median age was 82 years, and 41.4% had stage IV disease.
-
2 weeks ago | 
ophthalmologyadvisor.com | Erin Clancy
The US Food and Drug Administration (FDA) is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines and ultimately limit who can be vaccinated, according to a viewpoint by FDA officials that was published in The New England Journal of Medicine.1 The FDA will continue to evaluate individual applications for COVID-19 vaccines on a case-by-case basis, but the agency will adopt different standards for approval according to the patient populations...
